What is Neditol 2018-05-10T12:56:34+00:00



What is UUI and OAB?

Below you will find a brief overview of urgency, urge urinary incontinence (UUI), urinary frequency and overactive bladder (OAB) syndrome, which covers the definition, incidence in the UK and causes of UUI and OAB syndrome.

Urgency UI is involuntary urine leakage accompanied or immediately preceded by urgency (a sudden compelling desire to urinate that is difficult to delay).1

Patients with urgency or UUI often have increased urinary frequency (passing urine more often than normal).2

OAB is urgency that occurs with or without UUI and usually with increased frequency and nocturia.1

Urinary incontinence is thought to affect millions of people.3 UUI is most common in women and with increasing age.2,3 UUI is the second most common type of urinary incontinence.2 Approximately three out of 10 cases of urinary incontinence are due to UUI.2

UUI can be temporary or permanent.2

Temporary UUI
Causes of temporary urgency urinary incontinence include constipation, overhydration, alcohol and caffeine and cystitis.2

Permanent UUI
Causes of permanent urgency urinary incontinence include neurological diseases (i.e., multiple sclerosis and Parkinson’s disease), menopause, dementia and irritable bowel syndrome.2

OAB Syndrome
Although the cause of OAB syndrome is not fully understood, the bladder muscle appears to become overactive and squeeze when the bladder is not full.4 OAB syndrome may worsen with stress, caffeine and alcohol.4

References:? 1) NICE Clinical Guidelines. Urinary Incontinence: urinary incontinence in women: management. November 2015.?2) Patient. Urge Incontinence. http://patient.info/health/urge-incontinence (accessed 17/02/2017). 3) http://www.nhs.uk/Conditions/Incontinence-urinary/Pages/Introduction.aspx (accessed 17/02/2017). 4) Patient. Overactive Bladder. http://patient.info/health/overactive-bladder-syndrome (accessed 17/02/2017)

UUI and OAB Syndrome Resources
Please click the links below to leave the Aspire Pharma website and find out more information about UUI and OAB syndrome.




For further information please call: 01730 231148, email: info@www.soyporteno.com or visit www.www.soyporteno.com

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Neditol XL, please see the abbreviated prescribing information.
Revision reference – Neditol XL_16__27/02/2017